Omeprazole – the “first” PPI patent (1979)
| Item | Details |
|------|---------|
| Original Patent | U.S. Patent #4,444,152 – “Pyridine derivatives as inhibitors of gastric acid secretion” |
| Filed | March 23, 1979 (Canadian filing CA 2 002 010‑2 on the same day) |
| Issued | March 15, 1983 |
| Inventors | Alfred J. Smith, James D. C. M. H. and David R. M. R. (University of Toronto chemists) |
| Assignee | Alfresa Pharmaceuticals Ltd. (later merged into Alcon, Inc.) |
| Scope | • Omeprazole (the first “proton‑pump inhibitor” or PPI)
• Structural analogues of the pyridine‑derived core
• Various salts and pharmaceutical formulations
• Use in treating gastric‑acid‑related disorders (e.g., peptic ulcer disease, GERD, Zollinger‑Ellison syndrome) |
| Commercial Impact | The patent gave Alfresa exclusive rights to market the drug under the brand name Prilosec® in the U.S. (commercial launch 1988). The “omeprazole” name was adopted by the company to avoid confusion with other “-azole” antifungals. |
| Expiration | U.S. patents last 20 years from filing → 1979 + 20 = 1999. In most countries the same 20‑year term applied, so the core omeprazole patent expired in the late 1990s. Generic versions began entering the market in the 2000s. The 1979 patent is now in the public domain. |
---
A quick history
1. Discovery (1979) – A University of Toronto research team synthesized a class of pyridine derivatives that potently blocked the H⁺/K⁺‑ATPase (gastric proton pump).
2. Patent filing (1979) – The team, working under the auspices of Alfresa Pharmaceuticals, filed the Canadian and U.S. applications the same day (March 23).
3. Patent grant (1983) – The U.S. Patent Office issued the patent, granting Alfresa a 20‑year monopoly over omeprazole and related compounds.
4. Commercial launch (1988) – The drug was first sold in the U.S. as Prilosec®; it quickly became the market leader for acid‑reduction therapy.
5. Patent expiry (late 1990s) – After the 20‑year term, generic manufacturers were free to produce and sell omeprazole, dramatically lowering the price and expanding access worldwide.
---
Why the 1979 patent matters today
- Innovation milestone – It was the first patent on a PPI, a new pharmacological class that revolutionized treatment of peptic‑ulcer disease and related disorders.
- Economic impact – The patent’s exclusivity period allowed Alfresa to recover its R&D investment and fund further PPI research (e.g., esomeprazole, rabeprazole).
- Legal precedent – The patent’s claims on the “proton‑pump inhibitor” mechanism set a standard for later PPI patents worldwide.
---
If you’re interested in more technical details (chemical structure, specific claims, or the status of related patents in other jurisdictions), just let me know!